Showing 1,561 - 1,580 results of 102,734 for search '(( end point decrease ) OR ( 5 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.50s Refine Results
  1. 1561
  2. 1562

    SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
  3. 1563
  4. 1564
  5. 1565
  6. 1566
  7. 1567

    CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells. by Elif Aplak (7430123)

    Published 2020
    “…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
  8. 1568

    EphA4 immunostaining is decreased adjacent to injury site in ephrin-A5-Fc treated mice. by Yona Goldshmit (205708)

    Published 2011
    “…<p>Immunohistochemical analysis of (A,B) GFAP, (C–F) EphA4 and (G,H) CSPG expression at 2 weeks after spinal cord hemisection and 2 weeks of ephrin-A5-Fc treatment indicated that there was robust GFAP staining in both treated and control mice (A,B). …”
  9. 1569
  10. 1570
  11. 1571
  12. 1572
  13. 1573

    Sarcopenia as an Independent Risk Factor for Decreased BMD in COPD Patients: Korean National Health and Nutrition Examination Surveys IV and V (2008-2011) by Dong-Won Lee (2208223)

    Published 2016
    “…<div><p>Background</p><p>A decrease in bone mineral density (BMD) is a systemic consequence of chronic obstructive pulmonary disease (COPD). …”
  14. 1574
  15. 1575
  16. 1576
  17. 1577
  18. 1578
  19. 1579
  20. 1580

    Kami-shoyo-san improves ASD-like behaviors caused by decreasing allopregnanolone biosynthesis in an SKF mouse model of autism by Qing-Yun Guo (2007082)

    Published 2019
    “…However, the mechanisms by which GABAergic system dysfunctions induce the pathophysiology of ASD remain unclear. We previously demonstrated that a selective type I 5α-reductase inhibitor SKF105111 (SKF) induced ASD-like behaviors, such as impaired sociability-related performance and repetitive grooming behaviors, in male mice. …”